Sarepta Therapeutics
SRPT
108 hedge funds and large institutions have $559M invested in Sarepta Therapeutics in 2013 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 32 reducing their positions, and 44 closing their positions.
66% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 32
19% less funds holding
Funds holding: 134 → 108 (-26)
28% less call options, than puts
Call options by funds: $69.4M | Put options by funds: $96.4M
57% less capital invested
Capital invested by funds: $1.29B → $559M (-$727M)
57% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 44
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$35.8M |
| 2 |
VAM
Visium Asset Management
New York
|
+$25.3M |
| 3 |
BC
Broadfin Capital
New York
|
+$21.6M |
| 4 |
PA
Perceptive Advisors
New York
|
+$21.2M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$31.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$25.7M |
| 3 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$23.6M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$23.6M |
| 5 |
PC
PointState Capital
New York
|
-$22.9M |
SRPT Hedge Fund Activity: Q4 2013 in Review
108 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2013, worth a combined $559M — down 57% from $1.29B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of SRPT and 19 opened new positions — a net loss of 25 holders — while 32 trimmed existing stakes and 53 added.
The largest buyer was Columbia Wanger Asset Management, adding an estimated $35.8M. The largest seller was Lord, Abbett & Co, cutting an estimated $31.5M.
- 108 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2013, down from 134 in Q3 2013.
- Funds reported $559M of Sarepta Therapeutics stock for Q4 2013, down 57% quarter-over-quarter.
- 19 funds opened new Sarepta Therapeutics positions in Q4 2013 and 44 closed out, a net change of -25 holders.
- The largest Sarepta Therapeutics buyer in Q4 2013 was Columbia Wanger Asset Management, an estimated $35.8M added.
- The largest Sarepta Therapeutics seller in Q4 2013 was Lord, Abbett & Co, an estimated $31.5M sold.
Based on aggregated 13F filings for Q4 2013.